Latanoprost Actavis

Latanoprost, the active ingredient in Latanoprost Actavis, is a prostaglandin analog presented as a topical ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows EU quality standards and provides reliable global distribution.

Latanoprost is a prostaglandin analog used to reduce intra‑ocular pressure in ocular conditions. - Open‑angle glaucoma: reduces intra‑ocular pressure, helping to prevent progression of visual field loss. - Ocular hypertension: lowers eye pressure to reduce the risk of developing glaucoma. - Secondary open‑angle glaucoma: decreases pressure similarly to primary forms, aiding disease control.

Common Side Effects: - Increased iris pigmentation: gradual darkening of the iris color. - Eyelash changes: longer, thicker, or darker eyelashes. - Conjunctival hyperemia: mild redness of the eye. - Eye irritation: transient burning or stinging after instillation.

Serious or Rare Side Effects: - Uveitis: inflammation inside the eye requiring immediate medical attention. - Corneal edema: swelling of the cornea that can affect vision. - Severe allergic reaction: includes swelling, rash, or difficulty breathing.

Patients should be monitored for ocular changes and systemic considerations. - Monitor intra‑ocular pressure: schedule regular ophthalmic examinations. - Assess iris color change: inform patients about possible permanent pigmentation. - Avoid use in active ocular inflammation: contraindicated in uveitis or infections. - Caution in corneal disease: monitor closely for edema or decompensation. - Store at room temperature below 25°C: keep in the original container, protect from moisture and light.

Latanoprost may interact with other ocular or systemic agents. Major Interactions (Avoid): - Concurrent prostaglandin analogs: additive pressure‑lowering effect may cause hypotony. - Preservative‑containing anesthetic drops: increased ocular irritation. Moderate Interactions (Monitor Closely):\n- Non‑steroidal anti‑inflammatory eye drops: may exacerbate inflammation. - Beta‑blocker eye drops: additive intra‑ocular pressure reduction. - Systemic antihistamines: possible reduced ocular absorption.